ClinicalTrials.gg
TerminatedNCT04020926Updated Jun 25, 2020

Impact of Hyponatremia on Muscle Strength, Gait and Cognitive Function

An observational study in Hyponatremia, sponsored by Bürgerspital Solothurn. Terminated at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-25.

Sponsored by Bürgerspital Solothurn · Observational

Why this study was terminated
Study was stopped due to COVID-19 pandemic.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
8
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 17 studies in Hyponatremia with a site in Switzerland — 4 open to participants now, 4 under way, none of them phase 3. Hyponatremia · Switzerland.

Started
2019
the only one that year
Observational
5 of 17
1 open now
Registered
9th of 17
by date
Lead sponsor
1 of 17
Bürgerspital Solothurn

Among the 17 studies in Hyponatremia with a site in Switzerland, this one is the only one that started in 2019, is one of 5 observational ones, and was the 9th registered.

By phase

17 studies; the count open now beside each. This study's row is marked.

No phase6 · 3 open
Observationalthis study5 · 1 open
Phase 2/33 · 0 open
Phase 32 · 0 open
Phase 41 · 0 open

By the year they started

First in 2005; this study’s year is marked. 1 started in 2019.

Size and results

Median enrollment 79 across the 12 interventional studies, 232 across the 5 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 17 studies in Hyponatremia with a site in Switzerland, or all of them as a file.
02

Study summary

In this study patients with hyponatremia, defined as a serum sodium \< 126 mmol/L on admission to the hospital will be tested for muscular power by use of a hand grip dynamometer, for cognitive function by use of the Montreal-Cognitive-Assessment and gait stability by use of the Tinetti test. The tests will be performed on admission as well es after correction of hyponatremia.

Read the detailed description

The investigators broad objective is to examine in a prospective study whether an association exists between hyponatremia and psychomotor deficits. The specific aims are:

A.) To measure muscle strength by use of a dynamometer in patients presenting with moderate to severe hyponatremia (serum sodium ≤ 125 mmol/L) at the emergency department before and after correction of hyponatremia (serum sodium ≥ 135 mmol/L).

B.) To test for balance and gait disorders before and after correction of hyponatremia C.) To investigate whether presence of hyponatremia is associated with cognitive impairment that isreversible after correction of serum sodium.

The hypothesis is that hyponatremia is associated with reduced muscle strength, impaired balance, and cognitive impairment, and that the correction of the serum sodium will lead to an improvement of these parameters.

Design \& Setting

The investigators will conduct a single-center, prospective, observational study at the General Hospital Solothurn. The study will be conducted at the Department of Emergency Medicine, where patients will be screened for hyponatremia, and the Department of General Internal Medicine, where screening will occur both in the inpatient and outpatient services.

If a serum sodium of 125 mmol/L is detected in a blood sample sent from the Department of Emergency Medicine or General Internal Medicine, the Center for Laboratory Medicine will notify the study team responsible for patient enrollment using a dedicated pager. Then, a member of the study team will approach potential participants, inform them about the study goals and procedures, obtain informed consent, and enroll them into the study. Patients enrolled in the Department of Emergency Medicine needing hospitalization will primarily hospitalized in the Department of General Internal Medicine, unless hospitalization at specialist ward is indicated.

Patient enrollment criteria

Inclusion criteria Consecutive patients aged 18 years or above presenting with moderately to severe hyponatremia (serum sodium ≤ 125 mmol/L after correction for blood glucose), who give informed consent.

Exclusion criteria

  • Patients who do not give or are not able to give informed consent.
  • Patients with concomitant Potassium dysregulation (K+\<3.5 mmol/l or K+>5.0 mmol/l)

Baseline data collection

  1. Clinical data Of all patients included in the study, data on age, sex, comorbidities, and current medications taken by the patients will be gathered.
  2. Serum sodium measurements Measurements of serum sodium will be performed through the Center for Laboratory Medicine of the General Hospital Solothurn. Sodium determination will be performed by use of ion-selective electrode using the ICT (Na+, K+, Cl-) Sample Diluent Kit, Abbott Laboratories, Chicago, IL, USA. Additionally, serum osmolality, potassium, magnesium, calcium, creatinine, albumin and hemoglobin will be measured. All of these parameters are standard measurements in case of a severe electrolyte disorder and are part of clinical practice in the care for patients with electrolyte disorders. All laboratory parameters will be measured at baseline and after correction of serum sodium. In order to avoid multiple blood drawings for the patient the parameters mentioned above will be reordered from blood already taken for serum sodium determination.

Endpoints A.) Muscle strength in pounds and kilogram before and after correction of hyponatremia.

B.) Results for the Tinetti performance-oriented mobility assessment (POMA) to evaluate static and dynamic balance abilities during and after correction of hyponatremia.

C.) Results for the Montreal Cognitive Assessment (MOCA) test to assess mild cognitive impairment before and after correction of hyponatremia.

Muscle strength at handgrip will be measured at time of presentation at the clinic with a serum sodium ≤ 125 mmol/L and 24 to 48 hours after correction of hyponatremia at a serum sodium ≥ 135 mmol/L using the Jamar ® hydraulic hand dynamometer, Lafayette Instrument, Lafayette, IN, USA. Strength will be measured in pounds and kilograms thrice at baseline and after correction of hyponatremia, respectively. The best result of each test will be used for the analysis. The test will be conducted by either Drs. Woitok or Lindner.

The Tinetti POMA, a simple, easily administered test, will be used to measure patients' gait and balance taking about 10 to 15 minutes. Scoring of the Tinetti Assessment Tool is done on a three point ordinal scale with a range of 0 to 2. A score of 0 represents the most severe impairment, while a 2 would represent patient independence. The individual scores are then combined to form three measures; an overall gait assessment score, an overall balance assessment score, and a gait and balance score. The test has been validated in several studies and found to be a useful screening tool for gait instabilities and prediction of falls. The Tinetti POMA form is shown in the Appendix. The test will be performed at baseline and 24 to 48 hours after correction of hyponatremia. The test will be conducted by the study team.

The MOCA is a 30-point test administered in about 10 minutes designed to identify mild cognitive impairment. The test is validated for a large variety of diseases ranging from frontotemporal dementia to HIV or chronic obstructive pulmonary disease. The MOCA form is shown in the Appendix. The test will be performed at baseline and 24 to 48 hours after correction of hyponatremia. The test will be conducted by the study team.

Correction of hyponatremia Correction of hyponatremia will be performed at the discretion of the attending physician depending on the etiology of hyponatremia. Hypovolemic hyponatremia (diuretic induced hyponatremia, gastrointestinal fluid losses, low solute intake) will be corrected by use of an isotonic crystalloid to replenish volume deficits and in a next step, if needed, by use of loop diuretics to increase free water excretion and simultaneous substitution of fluid losses by isotonic crystalloids until normonatremia (i.e. serum sodium ≥ 135 mmol/L) is reached. If hyponatremia is due to adrenal insufficiency steroids will be applied in addition to volume resuscitation by use of isotonic crystalloids. In case of the syndrome of inappropriate anti diuretic hormone secretion water restriction will be ordered initially. Hyponatremia due to low effective circulating volume (heart failure, cirrhosis of the liver) will be corrected by salt and water restriction. Serum sodium corrections will be accompanied by frequent monitoring of serum sodium concentration. The study team will provide the managing physician at the ward current expert recommendations on the correction of hyponatremia in order to ensure best treatment for all study patients.

Sample size Sample size was calculated on basis of the MOCA test. To achieve a power of 90% and a two-sided alpha level of 0.05, the sample size needed to detect a difference of 5 points (shown difference between normal individuals and those with mild cognitive impairment) between the baseline and post-correction MOCA scores would be 44 patients. Thus, we plan to enroll a total of 50 patients.

Statistical analysis Data will be presented as means and standard deviation or medians and interquartile range as appropriate. Wilcoxon signed ranked tests will be used to compare results on muscle strength, Tinetti score and MOCA scores, since those are not normally distributed and samples will be dependent since every patient serves as his own control. A p-value of ≤ 0.05 will be considered statistically significant. Statistics will be calculated using SPSS Statistics, IBM Inc., Armonk, NY, USA.

Study period Based on general Patient count and prevalence of Hyponatremia, the enrollment of the sample size of 50 patients seems realistic in a 12-month period, starting on 01 September 2019.

03

Conditions studied

  • Hyponatremia

Browse trials for

Keywords

  • hyponatremia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

We will include all consecutive patients >/= 18 years with a serum sodium level \< 126 mmol/L on admission to the Hospital who give consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18 years or above
  • serum sodium ≤ 125 mmol/L
  • .

Exclusion criteria

Exclusion Criteria:

  • age \< 18 years
  • not give or are not able to give
  • K+\<3.5 mmol/l
  • K+>5.0 mmol/l)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
8 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Muscle strength

    A.) Change in muscle strength in kilogram before and after correction of hyponatremia.

    Time frame: Correction of hyponatremia (up to 1 week).

  2. Mobility assessment

    B.) Change in results for the Tinetti performance-oriented mobility assessment (POMA) to evaluate static and dynamic balance abilities during and after correction of hyponatremia.

    Time frame: Correction of hyponatremia (up to 1 week).

  3. Cognitive Function

    C.) Change in results for the Montreal Cognitive Assessment (MOCA) test to assess mild cognitive impairment before and after correction of hyponatremia.

    Time frame: Correction of hyponatremia (up to 1 week).

07

Study locations

1 site
  • Buergerspital Solothurn
    Solothurn, SO 4500, Switzerland
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Mar 2020, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2019
First posted
Jul 16, 2019
StartActual
Oct 1, 2019
Primary completionActual
Mar 31, 2020
CompletionActual
Mar 31, 2020
Last update
Jun 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04020926
Lead sponsor
Bürgerspital Solothurn
Responsible party
LINDNER Gregor (Director Dept. of Internal and Emergency Medicine, Bürgerspital Solothurn) — Principal investigator
First posted
Jul 16, 2019
Start date
Oct 1, 2019
Primary completion
Mar 31, 2020
Completion
Mar 31, 2020
Last update
Jun 25, 2020

Study contacts

Gregor Lindner, M.D.
principal investigator · Dept. of Internal and Emergency Medicine, Buergerspital Solothurn, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion